Charles Schwab
CMPX icon

Charles Schwab’s Compass Therapeutics CMPX Stock Holding History

Charles Schwab’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$664K Sell
303,139
-67,919
-18% -$201K ﹤0.01% 3146
2026
Q1 		$1.96M Sell
371,058
-39,099
-10% -$226K ﹤0.01% 2726
2025
Q4 		$2.2M Buy
410,157
+74,907
+22% +$346K ﹤0.01% 2734
2025
Q3 		$1.17M Buy
335,250
+61,778
+23% +$195K ﹤0.01% 2899
2025
Q2 		$711K Sell
273,472
-24,408
-8% -$50.3K ﹤0.01% 3010
2025
Q1 		$566K Buy
297,880
+11,689
+4% +$31.1K ﹤0.01% 3036
2024
Q4 		$415K Hold
286,191
– – ﹤0.01% 3194
2024
Q3 		$527K Hold
286,191
– – ﹤0.01% 3139
2024
Q2 		$286K Buy
286,191
+45,996
+19% +$67.2K ﹤0.01% 3377
2024
Q1 		$476K Sell
240,195
-5,817
-2% -$10.1K ﹤0.01% 3045
2023
Q4 		$384K Sell
246,012
-17,264
-7% -$29.9K ﹤0.01% 3167
2023
Q3 		$519K Buy
263,276
+11,880
+5% +$29.4K ﹤0.01% 3025
2023
Q2 		$799K Buy
251,396
+208,629
+488% +$655K ﹤0.01% 2842
2023
Q1 		$140K Hold
42,767
– – ﹤0.01% 3210
2022
Q4 		$215K Buy
42,767
+11,031
+35% +$44K ﹤0.01% 3174
2022
Q3 		$73K Buy
+31,736
New +$87.9K ﹤0.01% 3252

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's CMPX Position: Q2 2026 in Review

Charles Schwab reduced its Compass Therapeutics (CMPX) stake by 18% in Q2 2026, selling an estimated $201K and leaving 303,139 shares worth $664K. The position accounts for ﹤0.01% of the portfolio, ranked #3146.

Charles Schwab first reported a position in CMPX in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.2M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Charles Schwab held 303,139 shares of Compass Therapeutics worth $664K as of Q2 2026.
  • Charles Schwab sold 67,919 Compass Therapeutics shares in Q2 2026, an estimated $201K.
  • Compass Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3146 holding.
  • Charles Schwab first reported a position in Compass Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Charles Schwab's Compass Therapeutics position peaked at $2.2M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.